News

Virginia Innovation Partnership Corporation Introduces New Name of CIT GAP Funds: Virginia Venture Partners

Virginia Innovation Partnership Corporation (VIPC) has announced a new name for CIT GAP Funds: Virginia Venture Partners. The family of funds places equity investments in Virginia’s high-growth based technology, life science, and cleantech companies at the earliest developmental stages. This new name reflects the investment program’s renewed commitment to the Commonwealth and enduring partnerships with Virginia’s high-tech entrepreneurs.

“What we want to do is capitalize on the strengths that we have and build on those,” said Bob Stolle, President and CEO, VIPC. “Connecting innovators with opportunities is our business as we continue to work to provide the leadership necessary for funding, infrastructure and policy initiatives that support success for Virginia’s innovators, entrepreneurs, startups, market development and investment strategies. The renaming of the CIT GAP Funds to the Virginia Venture Partners reflects our new vision and mission as VIPC which is a critical part of the process.”

The mission of Virginia Venture Partners remains the same: invest in Virginia’s leading technology, clean tech and life science start-ups that have a high potential for achieving rapid growth and generating significant economic return for entrepreneurs, co-investors and the Commonwealth of Virginia. Additional goals of Virginia Venture Partners include increasing support for traditionally underrepresented entrepreneurs, enabling portfolio company creation of new jobs, and providing new outreach events and resources for startups.

“Since the fund’s inception in 2005, we have invested in over 260 portfolio companies and have achieved significant return on investment and socio-economic impact for the Commonwealth of Virginia. Our new name, Virginia Venture Partners, is an exciting transition that highlights the noteworthy state of innovation in our region,” said Tom Weithman, VIPC Chief Investment Officer and Managing Director of Virginia Venture Partners. “Our investment team remains as committed as ever to providing balanced support for Virginia’s high-growth early stage companies, including financial investment, access to our ever expanding network and trusted advisory services to portfolio companies.”

Virginia Venture Partners will retain the names of its core investment funds:

  • Flagship seed funds: GAP Tech, GAP Life Sciences, and GAP Clean Energy
  • Pre-Seed funds: Virginia Founders Fund, focused on women founders and founders of color; and Virginia Partners Fund, focused on investing in companies in traditionally underserved geographies and working with key partners throughout the Virginia ecosystem

According to its 2020 Impact Report, Virginia Venture Partners, as CIT GAP Funds, has catalyzed over $1.1B of investment from more than 1,000 third-party investors and has been acknowledged by CBI Insight as Virginia’s most active investor for seven successive years.

Read more on Globe Newswire.

 

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation